Ascentage Has First U.S. Biotech IPO of 2025, Elevating $126M to Convey Its Most cancers Meds to the World
Ascentage Pharma, a China-based drug developer with international ambitions, now has $126.4 million from a U.S. IPO that may primarily ...
Ascentage Pharma, a China-based drug developer with international ambitions, now has $126.4 million from a U.S. IPO that may primarily ...
